Apg-2575
Lymphoblastic Leukemia, Acute, Childhood
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Lymphoblastic Leukemia, Acute, Childhood cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Children's Oncology Group | Phase 3 | BBB |
(+)-VINCRISTINE Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BB |
N-Acetyl-L-Cysteine Teny Tjitra Sari | Phase 4 | BB |
Temsirolimus Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 | CCC |
Panobinostat Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Apg-2575 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →